Index
Technical Report Documentation Page
Introduction
Cannabis/Marijuana
Carisoprodol (and Meprobamate)
Cocaine
Dextromethorphan
Diazepam
Diphenhydramine
Gamma-Hydroxybutyrate (GHB, GBL,
and 1,4-BD)
Ketamine
Lysergic acid diethylamide (LSD)
Methadone
Methamphetamine (and Amphetamine)
Methylenedioxymethamphetamine
(MDMA, Ecstasy)
Morphine (and Heroin)
Phencyclidine (PCP)
Toluene
Zolpidem (and Zaleplon, Zopiclone)
Biographical Sketches of Lead
Authors and Main Contributors |
|
Zolpidem is a white to off-white crystalline powder.
Synonyms: N,N, 6-trimethyl-2-p-tolyl imidazo[1,2-a]pyridine
-3-acetamide L-(+)- tartrate; zolpidem tartrate; Ambien®.
Source: Zolpidem is available b y prescription
and is a Schedule IV controlled substance. Ambien® is available
in strengths of 5 mg and 10 mg (white and pink oval tablets, respectively).
Sonata® contains zaleplon. Imovane® contains zopiclone.
Drug Class: Non-benzodiazepine sedative-hypnotic,
CNS depressant, sleep aid. .
Medical and Recreational Uses: Zolpidem
is a non-benzodiazepine hypnotic used in short-term treatment (up to
4 weeks) of insomnia. Zaleplon and zopiclone also are indicated for
the treatment of insomnia.
Potency, Purity and Dose: Recommended zolpidem
dose is 10 mg immediately before bedtime (5 mg in the elderly). Recommended
nighttime zaleplon and zopiclone doses are 5-20 mg and 7.5 mg, respectively.
Patients treated with zolpidem often concurrently use other medications
such as antidepressants, narcotic analgesics, and muscle relaxants
Route of Administration: Oral.
Pharmacodynamics: While zolpidem has a chemical
structure unrelated to benzodiazepines, it is a GABA A receptor agonist
and shares some of the pharmacological properties of benzodiazepines.
Zolpidem p referentially binds to receptors containing an a 1 subunit
(also known as BZ1 - or w 1-receptor subtype s). Zolpidem shortens sleep
latency and prolongs total sleep time in patients with insomnia, but
has little effect on the stages of sleep in normal subjects. It also
has weak anticonvulsant properties. Zaleplon binds preferentially to
BZ-1, but also to BZ-2 and BZ-3; while zopiclone binds equally to BZ-1
and BZ-2. .
Pharmacokinetics: Zolpidem is absorbed readily
from the gastrointestinal tract. First-pass hepatic metabolism results
in an oral bioavailability of 67%, and 92% is bound in plasma. Zolpidem
has a short elimination half-life (2.2 + 0.4 hours), which is reduced
in children (~ 1.4 hours) and increased in the elderly (~ 2.8 hours)
and patients with hepatic cirrhosis (~ 9.9 hours) 6. Peak plasma concentrations
are detected at 1.5-2.5 hours. Peak concentrations are decreased with
food and increased in patients with hepatic insufficiency. Zaleplon
has a bioavailability of 30% and has a shorter half-life (1.1 hours)
compared to zolpidem.
Molecular Interactions / Receptor Chemistry: Zolpidem
is converted to hydroxylated metabolites principally by cytochrome P450
3A4 isoenzymes, with minor contributions by 1A2 and 2C9 isoforms. Potential
inhibitors of these isoenzymes could decrease the rate of zolpidem elimination
if administered concurrently, while potential inducers
could increase the rate of elimination
Blood to Plasma Concentration Ratio: Data
not available.
Interpretation of Blood Concentrations: Single
doses of 5 mg zolpidem resulted in average peak concentrations of 0.06
mg/L at 1.6 hours; 10 mg produced 0.12 mg/L at 1.6 hours; 15 mg produced
0.20 mg/L at 1.5 hours; and 20 mg produced 0.23 mg/L at 2.1 hours.
Interpretation of Urine Test Results: Urinary
excretion of unchanged zolpidem is less than 1%.
Effects:
Psychological: Sleep induction, drowsiness, dizziness, lightheadedness,
amnesia, confusion, concentration difficulties, and memory impairment
.
Physiological: Nausea, ataxia, slow and slurred speech, slow
reflexes, and difficulty with coordination.
Side Effect Profile: Somnolence, lightheadedness,
vertigo, he a dache, nausea, fatigue, cognitive deficits, and impairment
of consciousness ranging from somnolence to light coma, vertigo. Infrequently
reported side effects include agitation, decreased cognition, depressive
syndrome, detachment, concentration difficulties, nightmares, hallucination,
leg cramp, paresthesia, somnolence, speech disorder, double vision, dry mouth, and diarrhea. Hangover effects are unlikely with zolpidem,
although morning-after anterograde amnesia may occur. In overdose, patients
mainly suffer somnolence and drowsiness, pinpoint pupils, respiratory
depression, and in extreme cases, coma and respiratory failure.
Duration of Effects: Following 10-20 mg oral
doses of zolpidem, - 15effects can last 4up to 4-5 hours (dose-dependent).
There are generally no residual effects the morning after a nighttime
dose of zolpidem. Sedation may extend for 8-16 hours following intoxication.
Zaleplon has a more rapid onset and shorter duration of effects compared
to zolpidem, while zopiclone has longer duration of effects.
Tolerance, Dependence and Withdrawal Effects: Tolerance
and dependency are not typically detected after 4 weeks of therapeutic
use; however, tolerance may develop with chronic use. There is some
evidence of tolerance and physical dependency observed with chronic
administration of zolpidem in animal models. Withdrawal following abrupt
discontinuation may include mild dysphoria and insomnia, abdominal and
muscle cramps, vomiting, sweating, tremors, convulsions, fatigue, flushing,
lightheadedness, nervousness, and panic attacks.
Drug Interactions: Imipramine has an additive
effect of decreased alertness; chlorpromazine has an additive effect
of decreased alertness and decreased psychomotor performance; ritonavir
decreases clearance though inhibiting CYP3A hydroxylation; ketoconazol
also decreases clearance; and flumazenil is an effective and therapeutic
pharmacodynamic antagonist. Alcohol increases the sedation and decreases
psychomotor performance produced by zolpidem. Other CNS depressant drugs
may potentiate the effects of zolpidem. Zopiclone has additional performance
decrements when concurrently taken with alcohol, carbamazepine, and
diazepam.
Performance Effects: Unsteady gait, confusion,
disorientation, and significant cognitive and psychomotor impairment
can be observed within 1-5 hours following zolpidem doses of 10-20 mg.
Memory impairment (learning, recall and recognition of words,
pictures recall, and numbers) digit entry and recall psychomotor slowing (digit symbol substitution task, circular light tasks), reduced attentional
capacity (impaired divided and sustained attention), impaired balance
(ataxia, dizziness), visual disturbances ( Ataxia, double vision ), dizziness, nausea, and, impaired time estimation have been recorded
Psychomotor impairment can be found up to 5 hours after a single 15
mg oral dose and up to 8.25 hours after a 20 mg dose.
Memory and learning impairment can be found up to 8.25 hours following
a 10- 20 mg dose . Impaired coordination, reactive and cognitive skills.There
has been no significant residual effect on memory or actual driving
when subjects have been tested the morning after a single 10 mg dose.
Following a single 10-20 mg dose of zaleplon, studies have shown no
residual effects on actual driving (5-10 hours) or on body sway, reasoning,
retrieval and spatial memory (4-9 hours); however, significant impairment
has been reported within 1-3 hours of dosing. Minor impairment of delayed
free recall has occurred 4 hours after 20 mg dose of zaleplon. For zopiclone,
a single 7.5 mg dose can cause severe residual effects on actual driving
at 5 and 10 hours, severe residual effects on body sway and memory at
4 hours, and minor impairment of delayed free recall 9 hours after dosing.
Effects on Driving: The drug manufacturer
states that patients should be cautioned against engaging in hazardous
occupations requiring complete mental alertness or motor coordination
such as driving a motor vehicle. Within the first 4-5 hours, zolpidem
can produce significantly impaired coordinative, reactive and cognitive
skills following single oral doses of 10-20 mg. However, n o significant
adverse effects were observed during a 1.5 hour driving test on a rural
road, 10-12 hours after drug administration. In five reported cases
of driving impairment in which zolpidem was the only drug detected,
blood concentrations of zolpidem ranged from 0.08 to 1.4 mg/L (mean
0.65 mg/L). Symptoms and observed behavior included erratic driving
(weaving, lane travel), slow and slurred speech, slow reflexes, dazed
appearance, disorientation, confusion, loss of balance and coordination,
loss of short-term memory, blacking out, somnolence, dilated pupils,
double vision, poor performance on field sobriety tests, poor attention,
and an inability to stand or walk unassisted. In another six reported
cases of driving under the influence of zolpidem, blood concentrations
ranged from 0.1 to 0.73 mg/L (mean 0.31 mg/L). The subjects were involved
in automobile accidents or were seen to drive erratically, and symptoms
included slow and slurred speech, ataxia, unsteady gait, confusion and
disorientation.
DEC Category: CNS depressant
DEC Profile: Horizontal gaze nystagmus present;
vertical gaze nystagmus present for high doses; lack of convergence
present; pupil size normal; reaction to light slow; pulse rate down;
blood pressure down; body temperature normal. Other characteristic indicators
may include slow and slurred speech, somnolence, and poor performance
on field sobriety tests.
Panel’s Assessment of Driving Risks: Zolpidem
causes significant effects when driving within 5 hours of use (10 mg
dose). Zaleplon causes significant impairment within 3 hours of use
(10 mg), but no significant impairment after 4 hours (10 mg) and 5 hours
(20 mg). Zolpidem and zaleplon are relatively free of residual morning-after
effects. Zopiclone causes severe impairment 1-5 hours after dosing (7.5
mg), with residual hangover effects up to 10-11 hours.
References and Recommended Reading:
Baselt RC. Drug effects on psychomotor performance. Biomedical
Publications, Foster City, CA; pp 451-3, pp 456-9, pp 460-4;2001.
Mattila MJ, Vanakoski J, Kalska H, Seppälä T. Effects of
alcohol, zolpidem, and some other sedatives and hypnotics on human performance
and memory. Pharm Biochem Behav 1990;59(4):917-923.
DeClerk AC, Bissebe JC. Short-term safety profile of zolpidem. Objective
measures of cognitive effects. Eur Psychiat 1997;12(Suppl 1):15S-20S.
Garnier R, Guerault E, Muzard D, Azoyan P, Chaumet-Riffaud AE, Efthymiou
M-L. Acute zolpidem poisoning – Analysis of 344 cases. J Tox
Clin Tox 1994;32(4):391-404.
Greenblatt DJ, von Moltke LL, Harmatz JS, Merzanis P, Graf JA, Durol
AL Counihan M, Roth-Schecter B, Shader RI. Kinetic and dynamic interaction
of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin
Pharmac Therap 1998;64(6):661-7.
Hindmarch I, Patat A, Stanley N, Paty N, Rigney I. Residual effects
of zaleplon and zolpidem following middle of the night administration
five hours to one hour before awakening. Human Psychopharmac 2001;16(2):159-67.
Holm KJ, Goa KL. Zolpidem: An update of its pharmacology, therapeutic
efficacy and tolerability in the treatment of insomnia. Drugs 2000;59(4):865-89.
Isawa S, Susuki M, Uchiumi M, Murasaki M. The effect of zolpidem and
zopiclone on memory. Jap J Psychopharmac 2000;20(2):61-9.
Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic
and pharmacokinetic properties and therapeutic potential. Drugs 1990;40(2):291-313.
Lheureux P, Debailleul G, De Witte O, Askenasi R. Zolpidem intoxication
mimicking narcotic overdose: Response to flumazenil. Hum Exp Tox 1990;9(2):105-7.
Logan BK, Couper FJ. Zolpidem and driving impairment. J Forensic
Sci 2001;46(1):105-10. Mattila MJ, Vanakoski J, Kalska H, Seppala T. Effects of alcohol,
zolpidem, and some other sedatives and hypnotics on human performance
and memory. Pharmacol Biochem Behav 1998;59(4):917-23.
Meeker JEWhat is MMUCC
MMUCC Committee
MMUCC Documents
What is MMUCC?
The Model Minimum Uniform Crash Criteria (MMUCC) is a minimum set of crash data elements with standardized definitions that are relevant to injury control, highway and traffic safety. Not all of the MMUCC data elements need to be collected by police at the scene. Instead, some can be created from other data elements, such as the Vehicle Identification Number, to identify a specific vehicle characteristic. Or they can be obtained after linkage to other traffic records, such as injury or roadway inventory data to describe injury outcome or a specific roadway characteristic.
FOR MORE INFORMATION ON THE MMUCC, PLEASE CLICK ON
www-nrd.nhtsa.dot.gov/departments/nrd-30/ncsa/MMUCC.html
Top of Page
MMUCC Committee
Acknowledgements
The development of the Guideline for Minimum Uniform Crash Criteria (MMUCC) is being sponsored by the National Association of Governors' Highway Safety Representatives, the National Highway Traffic Safety Administration, and the Federal Highway Administration. Numerous state and local agencies and organizations have contributed staff to its development. The participation of the following individuals is recognized:
Frank Carlile
David Dickens
Doug Donscheski
Scott Falb
Rosa Gill
Dick Harmon
Don Hillis
David Kleppe
David Lawrence
Lance Mathess
Creighton Miller
David Mosley
Phil Salzberg
Manu Shah
James Templeton
Robert Thompson
John Watson
Ralph Craft
Dennis Flemons
Carl Hayden
Janet Johnson
Sandy Johnson
Janet Kumer
Tina Morgan
Ed Milton
Jack Oates
Barbara Rhea
Jackie Schraf
David Sleet
Carol Tan Esse
Dennis Utter
David Bozak
Noel Bufe
Charles Compton
Barbara Harsha
Roy Lucke
Gary March
Matt Snyder
Richard Pain
Charles Peltier
Patricia Waller Florida Department of Transportation
Charleston West Virginia Police
Nebraska State Patrol
Iowa Department of Transportation
North Carolina State Division of Motor Vehicles
Iowa Bureau of Emergency Medical Services
Missouri Department of Transportation
North Dakota State Highway Patrol
Louisiana Office of Public Health
Ohio State Patrol
South Dakota Office of Accident Records
Virginia Department of Motor Vehicles
Washington Traffic Safety Commission
Maryland State Highway Administration
Texas Department of Public Safety
Iowa Governor's Traffic Safety Bureau
New York State Department of Transportation
Federal Highway Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Center for Injury Prevention and Control
Federal Highway Administration
National Highway Traffic Safety Administration
InfoGroup, Inc.
Northwestern University Traffic Institute
University of Michigan Transportation Research Institute
National Association of Governors' Highway Safety Reps
Northwestern University Traffic Institute
March & Associates
International Association of Chiefs of Police
Transportation Research Board
International Association of Chiefs of Police
University of Michigan Transportation Research Institute
Top of Page
MMUCC Documents
To visit the MMUCC Homepage, please click on the following link:
Model Minimum Uniform Crash Criteria--Improving Crash Data for Safer Roadways
The following links will take you to several documents related to the MMUCC effort.
Download a PDF of the Final Guidelines (522KB) for Minimum Standardized Crash Data Reporting
,
Baselt RC . Six Cases cases of Impaired impaired driving
following recent use of the sleep inducer zolpidem (Ambien ®). Presented
at the AAFS American Academy of Forensic Sciences annual m eeting, NashvilleWhat is MMUCC
MMUCC Committee
MMUCC Documents
What is MMUCC?
The Model Minimum Uniform Crash Criteria (MMUCC) is a minimum set of crash data elements with standardized definitions that are relevant to injury control, highway and traffic safety. Not all of the MMUCC data elements need to be collected by police at the scene. Instead, some can be created from other data elements, such as the Vehicle Identification Number, to identify a specific vehicle characteristic. Or they can be obtained after linkage to other traffic records, such as injury or roadway inventory data to describe injury outcome or a specific roadway characteristic.
FOR MORE INFORMATION ON THE MMUCC, PLEASE CLICK ON
www-nrd.nhtsa.dot.gov/departments/nrd-30/ncsa/MMUCC.html
Top of Page
MMUCC Committee
Acknowledgements
The development of the Guideline for Minimum Uniform Crash Criteria (MMUCC) is being sponsored by the National Association of Governors' Highway Safety Representatives, the National Highway Traffic Safety Administration, and the Federal Highway Administration. Numerous state and local agencies and organizations have contributed staff to its development. The participation of the following individuals is recognized:
Frank Carlile
David Dickens
Doug Donscheski
Scott Falb
Rosa Gill
Dick Harmon
Don Hillis
David Kleppe
David Lawrence
Lance Mathess
Creighton Miller
David Mosley
Phil Salzberg
Manu Shah
James Templeton
Robert Thompson
John Watson
Ralph Craft
Dennis Flemons
Carl Hayden
Janet Johnson
Sandy Johnson
Janet Kumer
Tina Morgan
Ed Milton
Jack Oates
Barbara Rhea
Jackie Schraf
David Sleet
Carol Tan Esse
Dennis Utter
David Bozak
Noel Bufe
Charles Compton
Barbara Harsha
Roy Lucke
Gary March
Matt Snyder
Richard Pain
Charles Peltier
Patricia Waller Florida Department of Transportation
Charleston West Virginia Police
Nebraska State Patrol
Iowa Department of Transportation
North Carolina State Division of Motor Vehicles
Iowa Bureau of Emergency Medical Services
Missouri Department of Transportation
North Dakota State Highway Patrol
Louisiana Office of Public Health
Ohio State Patrol
South Dakota Office of Accident Records
Virginia Department of Motor Vehicles
Washington Traffic Safety Commission
Maryland State Highway Administration
Texas Department of Public Safety
Iowa Governor's Traffic Safety Bureau
New York State Department of Transportation
Federal Highway Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Center for Injury Prevention and Control
Federal Highway Administration
National Highway Traffic Safety Administration
InfoGroup, Inc.
Northwestern University Traffic Institute
University of Michigan Transportation Research Institute
National Association of Governors' Highway Safety Reps
Northwestern University Traffic Institute
March & Associates
International Association of Chiefs of Police
Transportation Research Board
International Association of Chiefs of Police
University of Michigan Transportation Research Institute
Top of Page
MMUCC Documents
To visit the MMUCC Homepage, please click on the following link:
Model Minimum Uniform Crash Criteria--Improving Crash Data for Safer Roadways
The following links will take you to several documents related to the MMUCC effort.
Download a PDF of the Final Guidelines (522KB) for Minimum Standardized Crash Data Reporting
,
TNWhat is MMUCC
MMUCC Committee
MMUCC Documents
What is MMUCC?
The Model Minimum Uniform Crash Criteria (MMUCC) is a minimum set of crash data elements with standardized definitions that are relevant to injury control, highway and traffic safety. Not all of the MMUCC data elements need to be collected by police at the scene. Instead, some can be created from other data elements, such as the Vehicle Identification Number, to identify a specific vehicle characteristic. Or they can be obtained after linkage to other traffic records, such as injury or roadway inventory data to describe injury outcome or a specific roadway characteristic.
FOR MORE INFORMATION ON THE MMUCC, PLEASE CLICK ON
www-nrd.nhtsa.dot.gov/departments/nrd-30/ncsa/MMUCC.html
Top of Page
MMUCC Committee
Acknowledgements
The development of the Guideline for Minimum Uniform Crash Criteria (MMUCC) is being sponsored by the National Association of Governors' Highway Safety Representatives, the National Highway Traffic Safety Administration, and the Federal Highway Administration. Numerous state and local agencies and organizations have contributed staff to its development. The participation of the following individuals is recognized:
Frank Carlile
David Dickens
Doug Donscheski
Scott Falb
Rosa Gill
Dick Harmon
Don Hillis
David Kleppe
David Lawrence
Lance Mathess
Creighton Miller
David Mosley
Phil Salzberg
Manu Shah
James Templeton
Robert Thompson
John Watson
Ralph Craft
Dennis Flemons
Carl Hayden
Janet Johnson
Sandy Johnson
Janet Kumer
Tina Morgan
Ed Milton
Jack Oates
Barbara Rhea
Jackie Schraf
David Sleet
Carol Tan Esse
Dennis Utter
David Bozak
Noel Bufe
Charles Compton
Barbara Harsha
Roy Lucke
Gary March
Matt Snyder
Richard Pain
Charles Peltier
Patricia Waller Florida Department of Transportation
Charleston West Virginia Police
Nebraska State Patrol
Iowa Department of Transportation
North Carolina State Division of Motor Vehicles
Iowa Bureau of Emergency Medical Services
Missouri Department of Transportation
North Dakota State Highway Patrol
Louisiana Office of Public Health
Ohio State Patrol
South Dakota Office of Accident Records
Virginia Department of Motor Vehicles
Washington Traffic Safety Commission
Maryland State Highway Administration
Texas Department of Public Safety
Iowa Governor's Traffic Safety Bureau
New York State Department of Transportation
Federal Highway Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
Federal Highway Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Highway Traffic Safety Administration
National Center for Injury Prevention and Control
Federal Highway Administration
National Highway Traffic Safety Administration
InfoGroup, Inc.
Northwestern University Traffic Institute
University of Michigan Transportation Research Institute
National Association of Governors' Highway Safety Reps
Northwestern University Traffic Institute
March & Associates
International Association of Chiefs of Police
Transportation Research Board
International Association of Chiefs of Police
University of Michigan Transportation Research Institute
Top of Page
MMUCC Documents
To visit the MMUCC Homepage, please click on the following link:
Model Minimum Uniform Crash Criteria--Improving Crash Data for Safer Roadways
The following links will take you to several documents related to the MMUCC effort.
Download a PDF of the Final Guidelines (522KB) for Minimum Standardized Crash Data Reporting
,
February etc 1996.
Physicians’ Desk Reference, Medical Economics Company,
Montvale, NJ, 2002.
Rush CR. Behavioral pharmacology of zolpidem relative to benzodiazepines:
a review. Pharmacol Biochem Behav 1998;61(3):253-69.
Salva P, Cosa J. Clinical pharmacokinetics and pharmacodynamics of
zolpidem: Therapeutic implications.
Clin Pharmacokin 1995;29(3):142-53.
Troy SM, Lucki I, Unruh MA, Cevallos WH, Leister CA, Martin PT, Furlan
PM, Mangano R. Comparison of the effects of zaleplon, zolpidem, and
triazolam on memory, learning, and psychomotor performance. J Clin
Psychopharmacol 2000;20(3):328-37.
Vermeeren A, O'Hanlon JF, Declerck AC, Kho L. Acute effects of zolpidem
and flunitrazepam on sleep, memory and driving performance, compared
to those of partial sleep deprivation and placebo. Acta Therapeutica
1995;21.
Volkerts ER, Verster JC, van Heuckelum JHG. The impact on car-driving
performance of zaleplon or zolpidem administration during the night. Eur
Neuropsychopharmacol 2000;10(Suppl 3):S395.
Wilkinson CJ. The abuse potential of zolpidem administered alone and
with alcohol. Pharmacol Biochem Behav 1998;60(1):193-202.
Wilkinson CJ. The acute effects of zolpidem, administered alone and
with alcohol, on cognitive and psychomotor function. J Clin Psychiatry 1995;56(7):309-18.
|